Compagnie Lombard Odier SCmA Takes Position in Elevance Health, Inc. (NYSE:ELV)

Compagnie Lombard Odier SCmA bought a new position in Elevance Health, Inc. (NYSE:ELV - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 2,543 shares of the company's stock, valued at approximately $1,106,000.

Several other large investors have also recently modified their holdings of the stock. Certuity LLC boosted its holdings in Elevance Health by 8.3% during the 4th quarter. Certuity LLC now owns 728 shares of the company's stock valued at $269,000 after acquiring an additional 56 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Elevance Health by 11.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 57,140 shares of the company's stock worth $20,904,000 after acquiring an additional 5,726 shares during the period. Van ECK Associates Corp raised its stake in shares of Elevance Health by 16.4% during the fourth quarter. Van ECK Associates Corp now owns 14,884 shares of the company's stock valued at $5,491,000 after acquiring an additional 2,102 shares in the last quarter. Naples Global Advisors LLC boosted its holdings in shares of Elevance Health by 38.1% in the fourth quarter. Naples Global Advisors LLC now owns 1,740 shares of the company's stock valued at $642,000 after purchasing an additional 480 shares during the period. Finally, Consolidated Planning Corp boosted its holdings in shares of Elevance Health by 9.1% in the fourth quarter. Consolidated Planning Corp now owns 931 shares of the company's stock valued at $343,000 after purchasing an additional 78 shares during the period. Institutional investors own 89.24% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on ELV. Argus set a $465.00 price target on Elevance Health in a research note on Friday, April 25th. Robert W. Baird reaffirmed a "neutral" rating and issued a $529.00 price target (down previously from $625.00) on shares of Elevance Health in a research report on Tuesday, April 15th. Truist Financial set a $500.00 price objective on shares of Elevance Health and gave the company a "buy" rating in a research note on Monday. Barclays lowered their target price on Elevance Health from $522.00 to $480.00 and set an "overweight" rating for the company in a report on Monday, June 2nd. Finally, Mizuho lifted their price target on Elevance Health from $455.00 to $505.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $498.87.

Insider Buying and Selling at Elevance Health

In related news, CFO Mark Kaye sold 4,588 shares of the business's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $424.82, for a total transaction of $1,949,074.16. Following the completion of the transaction, the chief financial officer now directly owns 18,977 shares in the company, valued at $8,061,809.14. The trade was a 19.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.29% of the company's stock.

Elevance Health Stock Down 0.4%

NYSE ELV traded down $1.73 during trading on Friday, hitting $384.49. The company's stock had a trading volume of 958,480 shares, compared to its average volume of 1,554,321. Elevance Health, Inc. has a fifty-two week low of $357.45 and a fifty-two week high of $567.26. The company has a market cap of $86.87 billion, a PE ratio of 15.01, a P/E/G ratio of 1.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The business's 50 day simple moving average is $405.63 and its 200-day simple moving average is $400.31.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Tuesday, April 22nd. The company reported $11.97 EPS for the quarter, topping analysts' consensus estimates of $10.60 by $1.37. The company had revenue of $48.77 billion during the quarter, compared to analysts' expectations of $46.26 billion. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. On average, equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be given a dividend of $1.71 per share. The ex-dividend date is Tuesday, June 10th. This represents a $6.84 dividend on an annualized basis and a yield of 1.78%. Elevance Health's dividend payout ratio is currently 26.69%.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.